Drug Design, Development and Therapy (Jan 2025)
Research Progress of SGLT2 Inhibitors in Cancer Treatment
Abstract
Xiaoyong Miao,1,* Jianing Zhang,2,* Weiyan Huang,2,* Yifei Wang,1 Aixia Jin,1 Jianping Cao,1 Zhenzhen Zhao3 1Department of Anesthesiology, Naval Medical Center, Naval Medical University, Shanghai, People’s Republic of China; 2Student Brigade, Changhai Hospital, Naval Medical University, Shanghai, People’s Republic of China; 3Department of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Zhenzhen Zhao, Department of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, 200433, People’s Republic of China, Email [email protected] Jianping Cao, Department of Anesthesiology, Naval Medical Center, Naval Medical University, Shanghai, 200050, People’s Republic of China, Email [email protected]: Sodium glucose co-transporter 2 (SGLT2) inhibitors represent a novel class of hypoglycemic drugs that have emerged in recent years. These inhibitors function primarily by blocking the reabsorption of glucose in the kidneys, specifically targeting the SGLT2 proteins in the proximal convoluted tubules. This inhibition results in the reduction of blood glucose levels through increased glucose excretion in the urine. Recent studies have identified SGLT2 expression in various cancer types, suggesting that SGLT2 inhibition can potentially suppress tumor growth. This article provides a comprehensive review of the role of SGLT2 in tumorigenesis and tumor progression, and explores the underlying mechanisms and potential therapeutic applications of SGLT2 inhibitors as anticancer agents.Keywords: SGLT2 inhibitors, SGLT2, cancer, mechanism
